EPISODE · May 5, 2021 · 52 MIN
PARP Inhibitors: Best Practices In Advanced Prostate Cancer Care In The Community
from AUAUniversity · host American Urological Association
This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31224 Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. Upon completion of this activity, participants will be able to: 1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice. 2. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer. 3. Discuss the impact of shared-decision making on patient and on patient-clinician communication. 4. Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.
What this episode covers
This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31224 Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. Upon completion of this activity, participants will be able to: 1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice. 2. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer. 3. Discuss the impact of shared-decision making on patient and on patient-clinician communication. 4. Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.
NOW PLAYING
PARP Inhibitors: Best Practices In Advanced Prostate Cancer Care In The Community
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.